scholarly journals Surgical treatment of the hepatocellular carcinoma with portal vein invasion

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e690
Author(s):  
O.G. Kotenko ◽  
O.O. Grinenko ◽  
O.O. Korshak ◽  
D.O. Fedorov ◽  
A.V. Gusev ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Treatment ◽  
Portal Vein ◽  
Portal Vein Invasion

Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion

2021 ◽  
Vol 266 ◽  
pp. 269-283
Author(s):  
Ahmed Shehta ◽  
Ahmed Farouk ◽  
Ahmed Nabieh Elghawalby ◽  
Mohamed Elshobary ◽  
Ahmed Aboelenin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Hepatic Resection ◽  
Portal Vein Invasion

Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion

2015 ◽  
Vol 40 (2) ◽  
pp. 402-411 ◽  
Author(s):  
Takatsugu Matsumoto ◽  
Keiichi Kubota ◽  
Taku Aoki ◽  
Yukihiro Iso ◽  
Masato Kato ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Resection ◽  
Portal Vein ◽  
Clinical Impact ◽  
Portal Vein Invasion ◽  
Anatomical Liver Resection

scholarly journals Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study

2020 ◽  
Vol 28 (1) ◽  
pp. 75-94 ◽  
Author(s):  
Junhui Sun ◽  
Guanhui Zhou ◽  
Xiaoxi Xie ◽  
Wenjiang Gu ◽  
Jing Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Portal Vein ◽  
Treatment Response ◽  
Transarterial Chemoembolization ◽  
Efficacy And Safety ◽  
Portal Vein Invasion ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
The Mean

The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9‐375) days, the 6-month PFS rate was 89.4 ± 2.1%, while the mean OS was 380 (95% CI: 370‐389) days, and the 6-month OS rate was 94.4 ± 1.7%. Multivariate logistic regression revealed that portal vein invasion (p = 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p = 0.040), previous cTACE treatment (p = 0.030), as well as abnormal serum creatinine level (BCr) (p = 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p = 0.011) and total serum bilirubin (TBIL) (p = 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1‐3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.

scholarly journals Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion

2018 ◽  
Vol 68 (4) ◽  
pp. 724-732 ◽  
Author(s):  
Carlo Spreafico ◽  
Carlo Sposito ◽  
Marta Vaiani ◽  
Tommaso Cascella ◽  
Sherrie Bhoori ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Prognostic Score ◽  
Portal Vein Invasion ◽  
Yttrium 90
Sign in / Sign up

Export Citation Format

Share Document